Biorithm, a MedTech company focused on women’s health, has successfully raised $3.5 million in Series A funding.
The round was co-led by Adaptive Capital Partners and SEEDS Capital, the investment arm of Enterprise Singapore, demonstrating strong investor confidence in Biorithm’s mission to revolutionize pregnancy care through innovative technology.
Headquartered in Singapore and with a strategic presence in Boston, USA, Biorithm is committed to addressing the global challenge of maternal health.
The company’s flagship technology, Femom, offers a groundbreaking approach to pregnancy care. It enables protocol-based remote monitoring of maternal and fetal biometrics, integrating predictive analytics to aid clinicians in early detection of potential complications.
This patient-friendly technology provides personalized guidance and facilitates seamless patient monitoring, aiming to reduce the daily mortality rate of 800 women worldwide due to childbirth complications.
Amrish Nair, Founder and CEO of Biorithm, expressed gratitude for the investor support, emphasizing the company’s dedication to improving maternal health and addressing the global collapse of maternal care.
He noted that socio-economic factors and limitations in current monitoring technologies are significant challenges, and the new investment is a testament to Biorithm’s mission to make proactive and connected healthcare accessible to every expectant mother.
The fresh capital injection will fuel Biorithm’s expansion in Southeast Asia and the USA. It will also support further research into the effectiveness of remote care and expansion of clinical trials, having already achieved success in Singapore and the United Kingdom.
Biorithm’s strategy includes forming key global partnerships to strengthen the women’s health ecosystem.
Investors have praised the startup’s vision and impact. Shi Ying, Founder & Managing Partner of Adaptive Capital Partners, highlighted the importance of connected medical care in predicting and diagnosing complications, while Tan Kaixin of SEEDS Capital underscored the company’s potential in revolutionizing the global maternal health market through technology-enabled remote monitoring.
With this funding, Biorithm is poised to set new standards in maternal healthcare, making quality care more accessible and effective for expectant mothers worldwide.
AsiaTechDesk.com